GLp-1s
Can GLP-1 drugs help with type 1 diabetes?
A growing number of people with type 1 diabetes are becoming overweight or obese, in part because insulin can cause weight gain. This has led many type 1 patients to try GLP-1 drugs (approved for type 2 diabetes and obesity) off-label. A group of researchers set out to study these patients and found that the GLP-1 drugs appeared to help, according to an abstract at the annual meeting of the European Association for the Study of Diabetes.
In the observational study of around 100 patients, those on Novo Nordisk's semaglutide (Ozempic/Wegovy) and Eli Lilly's tirzepatide (Mounjaro/Zepbound) lost 9% and 21% of their weight over one year, respectively, compared with a 0.4% weight gain in the control group. People on semaglutide and tirzepatide also saw A1C decreases of 0.42 and 0.62, respectively, compared with a 0.02 increase in the control group.
The researchers said that there were no reported hospitalizations from severe low blood sugar or ketosis during the trial.
These are early, observational data, though, and the researchers said that larger, prospective trials are needed to better understand the efficacy and safety of GLP-1 drugs in this population.
infectious disease
Gilead's long-acting antiviral succeeds again
Gilead's twice-yearly antiviral, called lenacapavir, reduced the risk of HIV infections by 96% compared to an expected rate of infection.
This study — which enrolled cisgender men, transgender women, transgender men, and gender nonbinary individuals who have sex with partners assigned male at birth — was the second pivotal trial the company was waiting for to file for the drug to be used in pre-exposure prophylaxis, or PrEP.
This first trial was also positive, showing that the antiviral protected women against HIV.
Read more.
podcast
What's next for Summit after its immunotherapy win?
Who's the iconoclastic outsider behind Summit's success? Why can't Moderna turn a profit? And should we be giving weight loss drugs to kids?
We discuss all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. Our colleague Matt Herper joins us to break down this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan.
We also chat about the latest news in biotech, including Moderna pruning its pipeline, plus results from a study that tested a GLP-1 drug in children.
Listen here.
No comments